MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination
Erin JungmeyerCompared to chemotherapy alone, the addition of the EGFR-MET bispecific antibody significantly prolonged progression-free survival after subsequent therapy, said Dr. Ryan Gentzler during the European Lung Cancer Congress. Read more
Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm?
Erin JungmeyerIn a recent interview, Dr. Lecia V. Sequist, a member of the team behind the Sybil AI algorithm, discusses how technology may soon be able to predict who will develop lung cancer. Read more
FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm
Erin JungmeyerDuring the European Lung Cancer Congress, Dr. Natalia Valdiviezo presented the data, which favored frontline osimertinib plus chemotherapy compared to osimertinib alone for patients with EGFR-mutated NSCLC. Read more
Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC
Erin JungmeyerIn light of data from FLAURA2 and MARIPOSA, Drs. Suresh Ramalingam and Joshua Sabari weighed the pros and cons during the 2024 TTLC meeting. Read more
Should Biomarkers Be Used in the Clinical Management of ES-SCLC?
Erin JungmeyerDuring a recent debate, Drs. Anne Chiang and Stephen Liu offered differing perspectives on the feasibility of biomarker use in the small-cell lung cancer space. Read more
Debaters Argue Merits of Surgery in Malignant Meso in Light of MARS2 Data
Erin JungmeyerSurgeon Erin Gillaspie, MD, said surgery still has a role in the treatment of mesothelioma while medical oncologist Hedy Kindler, MD, said newer systemic therapies make surgery obsolete in this space. Read more
Dr. Mark Kris, who leads the IASLC Pathologic Response Project, recently provided an update on efforts to collect data to confirm whether pathologic complete response can predict long-term outcomes. Read more
Multidisciplinary Team to Chair 2025 World Conference
Erin JungmeyerDrs. Umberto Malapelle, Jarushka Naidoo, Isabelle Opitz, and Noemí Reguart will lead WCLC when it returns to Barcelona September 6-9, 2025. Read more
Abstract Submissions, Reviewer Workshop Applications Open for WCLC
Erin JungmeyerThe 2024 World Conference on Lung Cancer may still be months away, but with deadlines approaching, now is the time to submit scientific abstracts and applications for the JTO manuscript reviewer workshop. Read more
Modified Lung Cancer Screening Eligibility Requirements May Reduce Racial Disparities in Lung Cancer Screening, Treatment
Erin JungmeyerAccording to research presented during the North America Conference on Lung Cancer, moving away from pack-years of smoking history to duration of smoking history would increase the number of Black patients who qualify for screening to a rate comparable to that of white patients. Read more